Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
The DNA damage response (DDR) pathway and its core component tumor suppressor p53 block cell cycle progression after genotoxic stress and represent an intrinsic barrier preventing cancer development. The serine/threonine phosphatase PPM1D/Wip1 inactivates p53 and promotes termination of the DDR pathway. Wip1 has been suggested to act as an oncogene in a subset of tumors that retain wild-type p53. In this paper, we have identified novel gain-of-function mutations in exon 6 of PPM1D that result in expression of C-terminally truncated Wip1. Remarkably, mutations in PPM1D are present not only in the tumors but also in other tissues of breast and colorectal cancer patients, indicating that they arise early in development or affect the germline. We show that mutations in PPM1D affect the DDR pathway and propose that they could predispose to cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. The PPM1D gene is mutated in selected cancer cell lines. (A) Whole-cell lysates from indicated cell lines were probed with anti-Wip1 (Bethyl Laboratories, Inc.), anti-Wip1 (Santa Cruz Biotechnology, Inc. [SC]), and anti–14-3-3 (loading control) antibodies. Note the additional Wip1-reactive band around 60 kD in U2OS and HCT116 cells. PC3 cells are p53 negative and served as a control. (B) Wip1 was depleted in U2OS and HCT116 cells by siRNA, and lysates were probed with the indicated antibodies. (C) Sequencing chromatograms of PPM1D from genomic DNA isolated from U2OS and HCT116 cells. Numbering is based on NCBI GenBank reference sequence NT_010783.15. Mutations are indicated by arrowheads and underlined. WT, wild-type PPM1D; Mut, mutated PPM1D; c., nucleotide sequence; p., Wip1 peptide sequence.](https://figures.cochat.ai/paper-figures/a55e0889191c480d83b569a3230ebde9/gain-of-function-mutations-of-ppm1d-wip1-impair-the-p53-dependent-g1-checkpoint-figure-1.jpg)

![Figure 3. Truncated Wip1 mutants show increased protein stability. (A) HCT116 and U2OS cells were treated for the indicated times with cycloheximide. Normalized cell lysates were probed using the monoclonal anti-Wip1 antibody (Santa Cruz Biotechnology, Inc. [SC]). (B) Signal intensity corresponding to the FL-Wip1 and truncated Wip1 from A was quantified using ImageJ software. The relative change in signal intensity is shown. Statistical significance was determined by unpaired two-tailed t test (n = 3; *, P < 0.05). (C) U2OS cells were treated with cycloheximide, proteasomal inhibitor MG132 or a combination of both for the indicated times and analyzed as in A. (D) U2OS cells were transfected with plasmid DNA coding for EGFP or EGFP fused to the C-terminal region of Wip1 (aa 380–605). Cells were treated for the indicated times with cycloheximide. Normalized cell lysates were probed with an anti-GFP antibody, and the signal intensity was quantified using ImageJ software. n = 3. Error bars indicate standard deviations. exp., exposure.](https://figures.cochat.ai/paper-figures/1244c669d3094b87aac15d5705c32b4a/gain-of-function-mutations-of-ppm1d-wip1-impair-the-p53-dependent-g1-checkpoint-figure-3.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this p53/pRb proficient cell line, p21 induction is impaired due to inefficient ATM response 72 and, probably, mutation of the Wip1 phosphatase that interferes with p53 activation.97”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · cited 2×
“Although high doses of DNA damage (such as therapeutic irradiation or radiomimetic drugs) lead to p53-induced programmed cell death or permanent withdrawal from the cell cycle (senescence), more moderate DNA damage (originating from erroneous DNA metabolism or from environmental factors) triggers expression of DNA rep…”
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“The most common example of such DDR defect is an inactivating somatic mutation in the TP53 gene that disables proper response to genotoxic stress, leads to genomic instability, and is found in about half of human tumors (Hollstein et al., 1991).”
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“In general, genotoxic stress induces stabilization, oligomerization, and binding of p53 to promoters, causing a widespread modulation of gene expression (Vogelstein et al., 2000).”
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 2×
“…ATM (ataxia telangiectasia mutated)/Chk2, ATR (ataxia telangiectasia and Rad3 related)/Chk1, and p38/ MK2 kinases converges on the tumor suppressor p53, which plays a central role in regulating cell fate decisions in response to genotoxic stress (Jackson and Bartek, 2009; Medema and Macůrek, 2012).”
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249 · cited 1×
“Whereas tumor development is substantially boosted by inactivation of the second allele of the tumor suppressor genes, monoallelic gain-offunction mutations are usually sufficient to activate oncogenes (Vogelstein and Kinzler, 2004).”
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 2×
“…identified oncogene-induced replication stress and DNA breakage that trigger the DDR as an intrinsic barrier against progression of early preinvasive stages of solid tumors to malignant lesions (Bartkova et al., 2005, 2006; Gorgoulis et al., 2005; Di Micco et al., 2006; Halazonetis et al., 2008).”
Visualizing Spatiotemporal Dynamics of Multicellular Cell-Cycle Progression
Sakaue-Sawano, A., Kurokawa, H., Morimura, T., Hanyu, A., Hama, H., Osawa, H., Kashiwagi, S., Fukami, K., Miyata, T., Miyoshi, H., et al. (2008) · Cell · doi:10.1016/j.cell.2007.12.033 · Cited by 2,173 · cited 2×
“A stable cell line expressing the fluorescent, ubiquitination-based cell cycle indicator (FUCCI) was generated by transduction of HCT116 cells with pCSII-EF-MCS-mKO2hCdt1(30–120) and pCSII-EF-MCS-mAG-hGeminin(1–110) plasmids (Sakaue-Sawano et al., 2008) followed by FACS sorting of double-positive cells from which a si…”
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · cited 1×
“…identified oncogene-induced replication stress and DNA breakage that trigger the DDR as an intrinsic barrier against progression of early preinvasive stages of solid tumors to malignant lesions (Bartkova et al., 2005, 2006; Gorgoulis et al., 2005; Di Micco et al., 2006; Halazonetis et al., 2008).”
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966 · cited 1×
“For example, germline mutations of oncogenic tyrosine kinases RET, MET, and KIT are linked with medullary thyroid carcinoma, hereditary papillary renal carcinoma, and hereditary gastrointestinal stromal tumor syndrome, respectively (Mulligan et al., 1993; Schmidt et al., 1997; Nishida et al., 1998).”
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
“Germline PPM1D mutations are associated with breast and ovarian cancer predisposition and may impair p53 function (Kleiblova et al., 2013).”
Backgroundthe St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2014) · Nature Genetics · doi:10.1038/ng.2938 · Cited by 1,105
Coombs, C. C., Zehir, A., Devlin, S. M., Kishtagari, A., Syed, A., Jonsson, P., Hyman, D. M., Solit, D. B., Robson, M. E., Baselga, J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.010 · Cited by 866
“PPM1D mutations were primarily protein-truncating variants in exon 6; these mutations have previously been demonstrated as gain-of-function mutations that lead to impaired TP53 function (Figure 1E) (Kleiblova et al., 2013).”
BackgroundPrognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776
Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies
Bowman, R. L., Busque, L., & Levine, R. L. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.01.011 · Cited by 448
“In addition to recurrent epigenetic modifiers (DNMT3A, TET2, and ASXL1), these studies identified recurrent mutations in TP53, PPM1D, ATM, and CHEK2, all of which play some role in the response to DNA damage (Kastan and Bartek, 2004; Kastenhuber and Lowe, 2017; Kleiblova et al., 2013).”
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy
Hsu, J. I., Dayaram, T., Tovy, A., De Braekeleer, E., Jeong, M., Wang, F., Zhang, J., Heffernan, T. P., Gera, S., Kovacs, J. J., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.10.004 · Cited by 425
The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma
Harms, P. W., Vats, P., Verhaegen, M. E., Robinson, D. R., Wu, Y.-M., Dhanasekaran, S. M., Palanisamy, N., Siddiqui, J., Cao, X., Su, F., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0702 · Cited by 345
The same, only different – DNA damage checkpoints and their reversal throughout the cell cycle
Shaltiel, I. A., Krenning, L., Bruinsma, W., & Medema, R. H. (2015) · Journal of Cell Science · doi:10.1242/jcs.163766 · Cited by 294
“mechanisms for cell cycle exit are often repressed (Bulavin et al., 2002; Kleiblova et al., 2013; Müllers et al., 2014).”
Self-citationSenescence from G2 arrest, revisited
Gire, V., & Dulić, V. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1000134 · Cited by 300
“In this p53/pRb proficient cell line, p21 induction is impaired due to inefficient ATM response 72 and, probably, mutation of the Wip1 phosphatase that interferes with p53 activation.(97) It is not clear, however, how p21-mediated nuclear translocation of cyclin B1Cdk1 complexes can induce senescence.”
BackgroundFly-FUCCI: A Versatile Tool for Studying Cell Proliferation in Complex Tissues
Zielke, N., Korzelius, J., van Straaten, M., Bender, K., Schuhknecht, G. F. P., Dutta, D., Xiang, J., & Edgar, B. A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.020 · Cited by 284
“, 2013), the response to DNA damage (Davoli and de Lange, 2012; Davoli et al., 2010; Kleiblova et al., 2013), the impact of growth (Son et al.”
BackgroundKahn, J. D., Miller, P. G., Silver, A. J., Sellar, R. S., Bhatt, S., Gibson, C., McConkey, M., Adams, D., Mar, B., Mertins, P., et al. (2018) · Blood · doi:10.1182/blood-2018-05-850339 · Cited by 225
“29 We performed protein half-life experiments using the protein synthesis inhibitor cycloheximide to study the protein stability of PPM1D-mutant hematopoietic cells.”
Transient Activation of p53 in G2 Phase Is Sufficient to Induce Senescence
Krenning, L., Feringa, F. M., Shaltiel, I. A., van den Berg, J., & Medema, R. H. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.007 · Cited by 193
Self-citationExome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas
Zhang, L., Chen, L. H., Wan, H., Yang, R., Wang, Z., Feng, J., Yang, S., Jones, S., Wang, S., Zhou, W., et al. (2014) · Nature Genetics · doi:10.1038/ng.2995 · Cited by 187
Orchestration of DNA Damage Checkpoint Dynamics across the Human Cell Cycle
Chao, H. X., Poovey, C. E., Privette, A. A., Grant, G. D., Chao, H. Y., Cook, J. G., & Purvis, J. E. (2017) · Cell Systems · doi:10.1016/j.cels.2017.09.015 · Cited by 169
“…cancer cell line which has an attenuated p53 response and an unstable G1 checkpoint due to the expression of truncated Wip1 and a p16 deficiency, both of which are important for overriding the G1 checkpoint (Diller et al., 1990; Stott et al., 1998; Akan et al., 2012; Kleiblova et al., 2013).”
BackgroundFUCCI sensors: powerful new tools for analysis of cell proliferation
Zielke, N., & Edgar, B. A. (2015) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.189 · Cited by 183
TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG)
Werbrouck, C., Evangelista, C. C. S., Lobón-Iglesias, M.-J., Barret, E., Teuff, G. L., Merlevede, J., Brusini, R., Kergrohen, T., Mondini, M., Bolle, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0126 · Cited by 158
“PPM1D-truncating mutations causing the loss of its regulatory domain were reported to negatively regulate TP53 activity through increased phosphatase activity at Ser15 of TP53 (39, 40).”
BackgroundKamada, R., Kudoh, F., Ito, S., Tani, I., Janairo, J. I. B., Omichinski, J. G., & Sakaguchi, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107622 · Cited by 139
Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma
Buczkowicz, P., & Hawkins, C. E. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00147 · Cited by 139
Jan, M., Ebert, B. L., & Jaiswal, S. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.10.002 · Cited by 116
“Mutations in PPM1D in clonal hematopoiesis truncate the C terminus of the protein[23,24], resulting in a gain-of-function protein with enhanced suppression of p53[85,86].”
Targeting the Checkpoint to Kill Cancer Cells
Benada, J., & Macůrek, L. (2015) · Biomolecules · doi:10.3390/biom5031912 · Cited by 124
“truncating mutations in several cancer types, including breast and ovary cancer, glioblastoma, and medulloblastoma [148,149]).”
BackgroundSelf-citationEvidence that the human cell cycle is a series of uncoupled, memoryless phases
Chao, H. X., Fakhreddin, R. I., Shimerov, H. K., Kedziora, K. M., Kumar, R. J., Perez, J., Limas, J. C., Grant, G. D., Cook, J. G., Gupta, G. P., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188604 · Cited by 124
The transcriptional landscape of Shh medulloblastoma
Skowron, P., Farooq, H., Cavalli, F. M. G., Morrissy, A. S., Ly, M., Hendrikse, L. D., Wang, E. Y., Djambazian, H. H. V., Zhu, H., Mungall, K. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21883-0 · Cited by 103
Müllers, E., Cascales, H. S., Jaiswal, H., Saurin, A. T., & Lindqvist, A. (2014) · Cell Cycle · doi:10.4161/15384101.2015.945831 · Cited by 84
Control of cell proliferation by memories of mitosis
Meitinger, F., Belal, H., Davis, R. L., Martinez, M. B., Shiau, A. K., Oegema, K., & Desai, A. B. (2024) · Science · doi:10.1126/science.add9528 · Cited by 90
“In particular, mutations that truncate and hyperactivate the p53-antagonizing phosphatase WIP1 (Kleiblova et al., 2013) were associated with loss of stopwatch function, and treatment with a WIP1 inhibitor (Gilmartin et al.”
BackgroundInfluentialInherited DNA lesions determine G1 duration in the next cell cycle
Lezaja, A., & Altmeyer, M. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1383578 · Cited by 84
Persistent repair intermediates induce senescence
Feringa, F. M., Raaijmakers, J. A., Hadders, M. A., Vaarting, C., Macurek, L., Heitink, L., Krenning, L., & Medema, R. H. (2018) · Nature Communications · doi:10.1038/s41467-018-06308-9 · Cited by 78
Self-citationMutant TP53 Posttranslational Modifications: Challenges and Opportunities
Nguyen, T.-A., Menendez, D., Resnick, M. A., & Anderson, C. W. (2014) · Human Mutation · doi:10.1002/humu.22506 · Cited by 69
“…and the overexpression of or a gain-of-function (GoF) mutation of PPMD1 (WIP1), the gene for a TP53-induced phosphatase that dephosphorylates TP53 as well as many other DNA damage response and repair proteins, or WIP1 overexpression [Lu et al., 2008; Zhu and Bulavin, 2012; Kleiblova et al., 2013].”
BackgroundPechackova, S., Burdova, K., Benada, J., Kleiblova, P., Jenikova, G., & Macurek, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7363 · Cited by 75
“Evaluation of the cell cycle checkpoints was performed as described previously with minor modifications [39].”
BackgroundMethodSelf-citationPediatric diffuse intrinsic pontine glioma: where do we stand?
Rashed, W. M., Maher, E., Adel, M., Saber, O., & Zaghloul, M. S. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09824-2 · Cited by 79
Jansen, S., Geuer, S., Pfundt, R., Brough, R., Ghongane, P., Herkert, J. C., Marco, E. J., Willemsen, M. H., Kleefstra, T., Hannibal, M., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.02.005 · Cited by 80
“As a regulator of the DDR, PPM1D plays an important role in cell-cycle control by positively upregulating G1to-S phase progression.(32) We hypothesized that the IDassociated mutations in PPM1D would lose this positive upregulation and thereby cause cells to stall in the G1-to-S phase, leading to reduced cell prolifera…”
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma
Fons, N. R., Sundaram, R. K., Breuer, G. A., Peng, S., McLean, R. L., Kalathil, A., Schmidt, M. S., Carvalho, D. M., Mackay, A. G., Jones, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11732-6 · Cited by 79
WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma
Richter, M. C., Dayaram, T., Gilmartin, A. G., Ganji, G., Pemmasani, S. K., Key, H. V. D., Shohet, J. M., Donehower, L. A., & Kumar, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0115635 · Cited by 73
“These carboxy terminal truncating mutations have also been identified in pediatric gliomas and colorectal tumors [26,28].”
BackgroundSmall molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R. (2014) · Apoptosis · doi:10.1007/s10495-014-0990-3 · Cited by 59
“For example overexpression of the WIP-1 phosphatase (dephosphorylates and inactivates p53) through gain of function mutations has been reported as means of inactivating p53 in human tumors [22].”
BackgroundTherapy-related myeloid neoplasms: does knowing the origin help to guide treatment?
Heuser, M. (2016) · Hematology · doi:10.1182/asheducation-2016.1.24 · Cited by 66
“Truncating PPM1D mutations are considered gain-of-function mutations that suppress p53 activity, impair the p53-dependent G1 checkpoint, and thus may lead to chemotherapy resistance and clonal outgrowth under chemotherapy.(25) In patients with ovarian cancer, PPM1D mutations were not found before treatment, but were p…”
BackgroundČekan, P., Hasegawa, K., Pan, Y., Tubman, E. S., Odde, D. J., Chen, J.-Q., Herrmann, M. A., Kumar, S., & Kaláb, P. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-01-0025 · Cited by 65
“Since the phosphatases Wip1 and PP4 promote the termination of the DDR signaling (Kleiblova et al., 2013; Shaltiel et al., 2014), the potential involvement of NCT”
BackgroundRiesco‐Eizaguirre, G., & Santisteban, P. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0202 · Cited by 71
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation
Khadka, P., Reitman, Z. J., Lu, S. D., Buchan, G. B. J., Gionet, G. L., Dubois, F. P. B., Carvalho, D. M., Shih, J., Zhang, S., Greenwald, N. F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28198-8 · Cited by 66
“1B), resulting in a truncated form of the protein phosphatase WIP1 which has previously been associated with a gain-of-function phenotype 11,15 .”
InfluentialKMTase Set7/9 is a critical regulator of E2F1 activity upon genotoxic stress
Lezina, L., Aksenova, V., Ivanova, T., Purmessur, N. S., Antonov, A. V., Tentler, D., Fedorova, O., Garabadgiu, A. V., Talianidis, I., Melino, G., et al. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.108 · Cited by 63
“We chose p53þ human osteosarcoma U2-OS cells, which exhibit a more pronounced arrest in G2/M in response to DNA damage due to overexpression of Wip1 phosphatase.(42)”
MethodWIP1 phosphatase as pharmacological target in cancer therapy
Pecháčková, S., Burdová, K., & Macůrek, L. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1536-2 · Cited by 60
“Besides amplification, nonsense mutations occur in a hotspot region of the exon 6 of PPM1D [61, 62].”
BackgroundSelf-citationThe role of PPM1D in cancer and advances in studies of its inhibitors
Deng, W., Li, J., Dorrah, K., Jimenez-Tapia, D., Arriaga, B., Hao, Q., Cao, W., Gao, Z., Vadgama, J. V., & Wu, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109956 · Cited by 57
“found that PPM1D gene mutation exists in colon cancer, which lead to the persistent suppression of p53 and the occurrence of tumors [24].”
BackgroundTruncating mutations of PPM1D are found in blood DNA samples of lung cancer patients
Zajkowicz, A., Butkiewicz, D., Drosik, A., Giglok, M., Suwiński, R., & Rusin, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.79 · Cited by 51
“Independently, this mutation was reported by others (Kleiblova et al, 2013).”
BackgroundResultInfluentialGutierrez‐Rodrigues, F., Groarke, E. M., Thongon, N., Rodríguez‐Sevilla, J. J., Catto, L. F. B., Niewisch, M. R., Shalhoub, R. N., McReynolds, L. J., Clé, D. V., Patel, B. A., et al. (2024) · Blood · doi:10.1182/blood.2024025023 · Cited by 51
Esfandiari, A., Hawthorne, T. A., Nakjang, S., & Lunec, J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0651 · Cited by 51
“1372C>T/Wt (R458X) gain-of-function (39) NGP N20R1 (P152T and P98H) Neuroblastoma Copy number gain (21) MCF-7 — Breast adenocarcinoma Amplified (38)”
BackgroundThe WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants
Buss, M. C., Remke, M., Lee, J. J., Gandhi, K., Schniederjan, M., Kool, M., Northcott, P. A., Pfister, S. M., Taylor, M. D., & Castellino, R. C. (2014) · Oncogene · doi:10.1038/onc.2014.37 · Cited by 49
Akamandisa, M. P., Nie, K., Nahta, R., Hambardzumyan, D., & Castellino, R. C. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz053 · Cited by 51
Wip1 phosphatase in breast cancer
Emelyanov, A., & Bulavin, D. V. (2014) · Oncogene · doi:10.1038/onc.2014.375 · Cited by 49
Small molecule activators of the p53 response
Ladds, M. J. G. W., & Laín, S. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz006 · Cited by 49
Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer
Lhotová, K., Stolařová, L., Zemánková, P., Vočka, M., Janatová, M., Borecká, M., Černá, M., Jelínková, S., Král, J., Volkova, Z., et al. (2020) · Cancers · doi:10.3390/cancers12040956 · Cited by 50
“Similarly to the previous studies describing its mosaic variants in OC patients [36–38], we also found mosaic gain-offunction mutations resulting in increased WIP1 phosphatase activity [38].”
ResultSelf-citationMönke, G., Cristiano, E., Finzel, A., Friedrich, D., Herzel, H., Falcke, M., & Loewer, A. (2017) · Scientific Reports · doi:10.1038/srep46571 · Cited by 45
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity
Sriraman, A., Radovanovic, M., Wienken, M., Najafova, Z., Li, Y., & Dobbelstein, M. (2016) · Oncotarget · doi:10.18632/oncotarget.9302 · Cited by 44
“The cell lines chosen for this study were MCF-7 (breast carcinoma) and U2OS (osteosarcoma), based on their known amplification (MCF-7) [23] or activating truncation (U2OS) [20] of Wip1.”
BackgroundMethodInfluentialTuri, Z., Šenkyříková, M., Mistrík, M., Bártek, J., & Moudrý, P. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1403685 · Cited by 44
“Such malfunction of the DNA-damage dependent p53 activation is due to the overexpression in U2OS cells of a truncated, mutant form of Wip1, a phosphatase that potently counteracts the otherwise functional phosphorylation of p53 under DNA damage conditions [40].”
BackgroundSoukupová, J., Zemánková, P., Lhotová, K., Janatová, M., Borecká, M., Stolařová, L., Lhota, F., Foretová, L., Macháčková, E., Stránecký, V., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195761 · Cited by 47
Self-citationGenetic variants and mutations ofPPM1Dcontrol the response to DNA damage
Dudgeon, C., Shreeram, S., Tanoue, K., Mazur, S. J., Sayadi, A., Robinson, R. C., Appella, E., & Bulavin, D. V. (2013) · Cell Cycle · doi:10.4161/cc.25694 · Cited by 44
“Recent reports suggested that the majority of C-terminal truncating mutations found in human cancers are gain-of-function.(18,21) However, here we identified the second most frequent mutation at position R552 as a loss-of-function mutation (Fig.”
BackgroundLossaint, G., Horvat, A., Gire, V., Bačević, K., Mrouj, K., Charrier‐Savournin, F., Georget, V., Fisher, D., & Dulić, V. (2022) · Journal of Cell Science · doi:10.1242/jcs.259114 · Cited by 43
Amelio, I., Antonov, A. V., Catani, M. V., Massoud, R., Bernassola, F., Knight, R. A., Melino, G., & Rufini, A. (2014) · Oncotarget · doi:10.18632/oncotarget.2667 · Cited by 42
Singhal, D., Kutyna, M., Hahn, C. N., Shah, M. V., & Hiwase, D. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0103 · Cited by 41
“As a result, PPM1D overexpression and mutations are believed to reflect at least partial inactivation of TP53 function (70).”
BackgroundUyanik, B., Goloudina, A. R., Akbarali, A., Grigorash, B. B., Petukhov, A., Singhal, S. K., Eruslanov, E. B., Chaloyard, J., Lagorgette, L., Hadi, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23330-6 · Cited by 43
DNA damage-induced regulatory interplay between DAXX, p53, ATM kinase and Wip1 phosphatase
Bražina, J., Švadlenka, J., Macůrek, L., Anděra, L., Hodný, Z., Bártek, J., & Hanzlíková, H. (2015) · Cell Cycle · doi:10.4161/15384101.2014.988019 · Cited by 38
Wang, Z., Xu, C., Diplas, B. H., Moure, C. J., Chen, C.-P. J., Chen, L. H., Du, C., Zhu, H., Greer, P. K., Zhang, L., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0507 · Cited by 39
“Truncated PPM1D mutants retain phosphatase activity and appear to be stabilized because of the loss of COOH-regulatory elements (7, 16, 17).”
BackgroundTherapy-related myeloid neoplasms
Ganser, A., & Heuser, M. (2016) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000316 · Cited by 39
Genetic Background of Polycythemia Vera
Regimbeau, M., Mary, R., Hermetet, F., & Girodon, F. (2022) · Genes · doi:10.3390/genes13040637 · Cited by 41
The catalytic role of the M2 metal ion in PP2Cα
Pan, C., Tang, J., Xu, Y., Xiao, P., Liu, H., Wang, H.-A., Wang, W., Meng, F., Yu, X., & Sun, J. (2015) · Scientific Reports · doi:10.1038/srep08560 · Cited by 34
Andrysík, Z., Sullivan, K. D., Kieft, J. S., & Espinosa, J. M. (2022) · Nature Communications · doi:10.1038/s41467-022-35089-5 · Cited by 33
Uncoding the genetic heterogeneity of myelodysplastic syndrome
Lindsley, R. C. (2017) · Hematology · doi:10.1182/asheducation-2017.1.447 · Cited by 33
“Mutations in PPM1D are localized to exon 6 and cause C-terminal truncations that may cause an increase in phosphatase activity that aberrantly inhibits checkpoint and DNA damage response pathways.(27)”
BackgroundKrześniak, M., Zajkowicz, A., Matuszczyk, I., & Rusin, M. (2014) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2014.06.002 · Cited by 31
“This and similar mutations in PPM1D could have important clinical implications (Ruark et al., 2013, Kleiblova et al., 2013).”
PPM1D in Solid and Hematologic Malignancies: Friend and Foe?
Zhang, L., Hsu, J. I., & Goodell, M. A. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-1018 · Cited by 33
“With the advent of next-generation sequencing, mutations in PPM1D were first reported in 2013 (25).”
BackgroundInfluentialZhang, M., Xu, E., Zhang, J., & Chen, X. (2015) · Oncogene · doi:10.1038/onc.2015.31 · Cited by 30
Ppm1d truncating mutations promote the development of genotoxic stress-induced AML
Burócziová, M., Daněk, P., Oravetzova, A., Chalupova, Z., Alberich-Jordà, M., & Macůrek, L. (2023) · Leukemia · doi:10.1038/s41375-023-02030-8 · Cited by 30
A FOXO-dependent replication checkpoint restricts proliferation of damaged cells
Hornsveld, M., Feringa, F. M., Krenning, L., van den Berg, J., Smits, L. M. M., Nguyen, N. B., Colman, M. J. R., Dansen, T. B., Medema, R. H., & Burgering, B. M. T. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108675 · Cited by 29
Self-citationBurócziová, M., Burdová, K., Martinikova, A. S., Kašpárek, P., Kleiblová, P., Danielsen, S. A., Borecká, M., Jeníková, G., Janečková, L., Pavel, J., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2057-4 · Cited by 24
“was partially supported by Worldwide Cancer Research foundation (14-1176), P.”
BackgroundSelf-citationPPM1D Is a Therapeutic Target in Childhood Neural Tumors
Milosevic, J., Treis, D., Fransson, S. M., Gallo-Oller, G., Sveinbjørnsson, B., Eißler, N., Tanino, K., Sakaguchi, K., Martinsson, T., Wickström, M., et al. (2021) · Cancers · doi:10.3390/cancers13236042 · Cited by 23
“Moreover, high expression and/or genetic aberration of PPM1D is frequently found in cancers with wtTP53, suggesting that high protein levels or stability of WIP1 inhibits the activity of p53, which can result in neoplastic transformation and malignant tumor formation [79,80].”
BackgroundFrom Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression
Gurnari, C., Fabiani, E., Falconi, G., Travaglini, S., Ottone, T., Cristiano, A., & Voso, M. T. (2021) · Biology · doi:10.3390/biology10020128 · Cited by 24
Copy number losses of oncogenes and gains of tumor suppressor genes generate common driver mutations
Besedina, E. G., & Supek, F. (2024) · Nature Communications · doi:10.1038/s41467-024-50552-1 · Cited by 23
“Thismaybeexplainedbyeitherofthe two (relatively rarely occurring) scenarios: instances of GoF truncating mutationsin OGs 38 – 40 and/orbygenesthatmay actaseither OGorTSG depending on the cancer type 41,42 and that we classed as OGs.”
Protein phosphatase, Mg2+/Mn2+‐dependent 1D (PPM1D) mutations in haematological cancer
Husby, S., Justesen, E. H., & Grønbæk, K. (2020) · British Journal of Haematology · doi:10.1111/bjh.17120 · Cited by 23
“Consistent with this, in vitro studies have shown that cells with truncating exon 6 PPM1D mutations show hampered p53 function and arrest in G1 (usually allowing for DNA repair), and thus might predispose the genome to accumulate tumour-inducing mutations.(10)”
BackgroundInfluentialPrevalence, causes and impact of TP53-loss phenocopying events in human tumors
Fito-Lopez, B., Salvadores, M., Álvarez‐Álvarez, M. M., & Supek, F. (2023) · BMC Biology · doi:10.1186/s12915-023-01595-1 · Cited by 22
Nahta, R., & Castellino, R. C. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114362 · Cited by 21
Harnessing p53 for targeted cancer therapy: new advances and future directions
Andrysík, Z., & Espinosa, J. M. (2025) · Transcription · doi:10.1080/21541264.2025.2452711 · Cited by 22
TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm
Beird, H. C., Yin, C. C., Khoury, J. D., Pierce, S. A., Abbas, H. A., Zhao, L., Skwarska, A., Qazilbash, M. H., Konopleva, M. Y., Futreal, P. A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022007879 · Cited by 19
“Truncating mutations (stopgain, frameshift, or splice) in TET2 are more likely to be deleterious than missense mutations, with an adverse impact on lifespan in a genome-wide association study of over 200 000 UK Biobank participants.15 They can lead to nonsense-mediated decay, loss of important catalytic domains, a tra…”
BackgroundSchaefer, E. J., & Lindsley, R. C. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.03.005 · Cited by 19
Milosevic, J., Fransson, S. M., Gulyás, M., Olsen, T. K., Gallo-Oller, G., Treis, D., Elfman, L. H. M., Wilhelm, M., Martinsson, T., Baryawno, N., et al. (2021) · Cancers · doi:10.3390/cancers13215493 · Cited by 19
“Moreover, high expression and/or genetic aberration of PPM1D is frequently found in cancers with wtTRP53 suggesting that high protein levels or stability of WIP1 inhibit the activity of p53 that can results in neoplastic transformation and malignant tumor formation [36,37].”
BackgroundMolecular Basis of Pediatric Brain Tumors
Κλώνου, Α., Piperi, C., Gargalionis, A. N., & Papavassiliou, A. G. (2017) · NeuroMolecular Medicine · doi:10.1007/s12017-017-8455-9 · Cited by 18
Cardoso, M., Paulo, P., Maia, S., & Teixeira, M. R. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22393 · Cited by 18
“Truncating mutations in PPM1D have previously been identified in patients with breast, ovarian, colorectal and lung cancer, and have been associated with an increased risk of cancer development (Kleiblova et al., 2013; Ruark et al., 2013; Akbari et al., 2014; Zajkowicz et al., 2015).”
BackgroundREST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature
Shaik, S., Kennis, B. A., Maegawa, S., Schadler, K., Yanwen, Y., Callegari, K., Lulla, R. R., Goldman, S., Nazarian, J., Rajaram, V., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23750 · Cited by 18
Therapeutically targeting the unique disease landscape of pediatric high-grade gliomas
Fernando, D., Ahmed, A. U., & Williams, B. R. G. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1347694 · Cited by 19
“Gain-of-function mutations within protein phosphatase, Mg 2+ /Mn 2+ dependent 1D (PPM1D), a wildtype p53-induced phosphatase 1 (Wip1), are another TP53 pathway-associated mediator of tumorigenesis which act independently of TP53 status to inhibit p53 activity (189).”
Storchova, R., Palek, M., Palková, N., Veverka, P., Brom, T., Hofr, C., & Macůrek, L. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1269 · Cited by 16
“Of note, high levels of active PPM1D are commonly present in cancer cells due to amplification of the chromosomal locus 17q23 or due to gain-of-function mutations in the last exon of PPM1D (11,12,65,81,82).”
BackgroundSmetana, K., Dvořánková, B., & Lacina, L. (2013) · Folia Biologica · doi:10.14712/fb2013059060207 · Cited by 17
“If the seriously damaged cells survive, they can cause cancer (Jackson and Bartek, 2009; Cha and Yim, 2013; Kleiblova et al., 2013) (Fig.”
BackgroundLZAP is a novel Wip1 binding partner and positive regulator of its phosphatase activity in vitro
Wamsley, J. J., Issaeva, N., An, H., Lu, X., Donehower, L. A., & Yarbrough, W. G. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1261767 · Cited by 16
Myeloid malignancies after treatment for solid tumours
Murthy, G. S. G., & Abedin, S. M. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.02.012 · Cited by 15
PPM1D activity promotes cellular transformation by preventing senescence and cell death
Stoyanov, M., Martinikova, A. S., Matějková, K., Horáčková, K., Zemánková, P., Burdová, K., Zemanová, Z., Kleiblová, P., Kleibl, Z., & Macůrek, L. (2024) · Oncogene · doi:10.1038/s41388-024-03149-3 · Cited by 14
“…others have previously shown that increased PPM1D activity resulting from the high protein level of the C-terminally truncated PPM1D provides cells with proliferation advantage upon exposure to various forms of genotoxic stress, including ionising radiation, etoposide and cytarabine [29, 31, 32].”
InfluentialSelf-citationKállai, A., Ungvari, A., Csabán, D., Őrfi, Z., Lehoczki, A., Harasztdombi, J., Yabluchanskiy, A., Benyó, Z., Szappanos, Á., Tarantini, S., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01654-1 · Cited by 16
“PPM1D mutations stabilize the protein, leading to suppressed DDR function like p53-mediated apoptosis; therefore, mutant clones can resist apoptosis and outperform normal HSCs especially when exposed to chemo-or radiation therapy [93, 144, 149, 150].”
Substrate spectrum of PPM1D in the cellular response to DNA double-strand breaks
Gräf, J. F., Mikičić, I., Ping, X., Scalera, C., Mayr, K., Stelzl, L. S., Beli, P., & Wagner, S. (2022) · iScience · doi:10.1016/j.isci.2022.104892 · Cited by 14
Łasut-Szyszka, B., Gdowicz‐Kłosok, A., Małachowska, B., Krześniak, M., Będzińska, A., Gawin, M., Pietrowska, M., & Rusin, M. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.110946 · Cited by 14
Fontana, M. C., Nanni, J., di Rorà, A. G. L., Petracci, E., Padella, A., Ghetti, M., Ferrari, A., Marconi, G., Soverini, S., Iacobucci, I., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9040388 · Cited by 14
“WIP1, the protein encoded by PPM1D, is overexpressed in many solid tumors, conferring a poor prognosis [16,51,52], while its deficiency causes defects in hematopoietic differentiation, immune system and inflammation [53].”
BackgroundPLK4 : Master Regulator of Centriole Duplication and Its Therapeutic Potential
Hamzah, M., Meitinger, F., & Ohta, M. (2025) · Cytoskeleton · doi:10.1002/cm.22031 · Cited by 13
“Two other cancer cell lines (HCT116, U2OS) harbored a truncation in Wip1 PPM1D , leading to stabilization and hyperactivation of its phosphatase domain, which in turn inhibited p53 (Kleiblova et al. 2013).”
Seipel, K., Frey, M., Nilius, H., Akhoundova, D., Banz, Y., Bacher, U., & Pabst, T. (2023) · Current Oncology · doi:10.3390/curroncol30120762 · Cited by 12
“PPM1D alterations are typically nonsense or frameshift mutations in exon 6, resulting in truncated protein products promoting cell proliferation [33,39,40].”
BackgroundThe p53 protein – not only the guardian of the genome
Rusin, M. (2024) · Postępy Biochemii · doi:10.18388/pb.2021_518 · Cited by 13
Yokoyama, A., Watanabe, K., Inoue, Y., Hirano, T., Tamaoki, M., Hirohashi, K., Kawaguchi, S., Ishida, Y., Takeuchi, Y., Kishimoto, Y., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq6740 · Cited by 12
PP2C phosphatases—terminators of suicidal thoughts
Lagorgette, L., Bogdanova, D. A., Belotserkovskaya, E., Garrido, C., & Demidov, O. N. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07269-2 · Cited by 10
Metadata
- Authors
- Kleiblova, P., Shaltiel, I. A., Benada, J., Ševčík, J., Pecháčková, S., Pohlreich, P., Voest, E. E., Dundr, P., Bartek, J., Kleibl, Z., Medema, R. H., & Macurek, L.
- Affiliations
- Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, CZ-12853 Prague, Czech Republic 1
- Division of Cell Biology, The Netherlands Cancer Institute, 1066CX Amsterdam, Netherlands 2
- Czech Academy of Sciences (CZ)
- Charles University (CZ)
- University Medical Center Utrecht (NL)
- Department of Cancer Cell Biology 4 and 5
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Medema, René H.
- Venue
- Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2013-05-06
- Volume
- 201
- Issue
- 4
- Pages
- 511-521
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- PMC
- PMC3653305
- OpenAlex
- W2096812573
- Cited by
- 170
- References
- 39
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 25 · 2023: 12 · 2022: 10 · 2021: 11 · 2020: 12 · 2019: 12 · 2018: 11 · 2017: 13 · 2016: 12 · 2015: 11 · 2014: 17 · 2013: 5
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Cell Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- ASEP (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- PPM1D, Wip1, gain-of-function mutations, p53, G1/S checkpoint, DNA damage response, tumor suppressor inactivation, breast cancer, colorectal cancer, germline mutations, cancer susceptibility, cell cycle arrest
- MeSH terms
- Protein Phosphatase 2C, Cell Cycle, DNA Damage, HeLa Cells, Humans, Mutation, Neoplasms, Phosphoprotein Phosphatases, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, G1 Phase, Genetic Predisposition to Disease, Cell Line, Tumor, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.